India Pharma Outlook Team | Tuesday, 15 July 2025
Sun Pharmaceutical Industries Ltd. has announced the availability of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S. to treat severe alopecia areata. This severe autoimmune disorder unpredictably causes hair loss in adult patients.
The availability of LEQSELVI to healthcare professionals and patients is one of the primary contributions to the U.S. dermatology product mix of Sun Pharma. It is an effective new treatment for people who have fewer available treatments.
Richard Ascroft, the Sun Pharma North America CEO, said, "LEQSELVI will give hope to patients and doctors who need quick and dependable results. This is another milestone that strengthens our goal of meeting unmet medical needs with innovation."
Follow-up clinical trials indicated that there was accelerated and significant hair growth, with a third of test subjects having almost full scalp coverage at Week 24. Notably, 3 percent of patients had 80 percent or more hair regrowth as early as week 8.
Also Read: How Indian Pharma Companies can Boost Global Market Access
Another such option, said Dr. Arash Mostaghimi, Associate Professor of Dermatology at Brigham and Women's Hospital, is LEQSELVI, which is based on a pill (capsule) that delivers consistent and fast improvements that can transform patients' lives.
The severe alopecia areata has great psychological costs. A survey carried out recently showed that 83 percent of patients consider the rapidly acting treatment as a priority. In LEQSELVI, both clinical and emotional needs will be addressed, and the improvements can be observed immediately.
Nicole Friedland, President and CEO of the National Alopecia Areata Foundation, said, "We are glad of this step up." LEQSELVI gives hope to suffering patients wanting a therapeutic option declared safe by the FDA.”
The introduction of LEQSELVI into the market by Sun Pharma is a significant step towards the provision of more treatment avenues to autoimmune hair loss in the United States.
